title: Preventing secondary cases of meningococcal disease by identifying and eradicating disease-causing strains in close contacts of patients.
abstract: In Norway, the use of chemoprophylaxis after cases of meningococcal disease is not recommended. Instead, household members less than 15 years are treated with penicillin for 7 days. Failures of this treatment have been reported. We therefore used DNA fingerprinting to identify the disease-causing strain in healthy contacts combined with selective rifampicin prophylaxis to these carriers to prevent secondary cases. During a 2-year period (1987-89) there were 13 cases of meningococcal disease in the County of Telemark (165000 inhabitants). 65 (14.7%) out of 441 contacts to these 13 patients harbored meningococci in their throat; 16 (3.6%) carried the disease-causing strain. Only 1 carrier fulfilled the criteria for being treated with penicillin; 8 were adults and the remaining 7 were not household members. No secondary cases of meningococcal disease occurred during the study period or the following 12 months. During the 4-year period (1984-87) preceding the study period there were 39 cases of meningococcal disease in Telemark; 7 of them were index cases for 12 bacteriologically verified and 4 clinically suspected secondary cases of meningococcal disease. We conclude that selective prophylaxis with rifampicin seems to be more efficient that penicillin treatment of household members less than 15 to prevent secondary cases of meningococcal disease.
authors.affiliation: A/S Telelab, Laboratory for Medical Microbiology, Skien, Norway.
authors.forename: B E
authors.initials: BE
authors.lastname: Kristiansen
authors.forename: Y
authors.initials: Y
authors.lastname: Tveten
authors.forename: E
authors.initials: E
authors.lastname: Ask
authors.forename: T
authors.initials: T
authors.lastname: Reiten
authors.forename: A B
authors.initials: AB
authors.lastname: Knapskog
authors.forename: J
authors.initials: J
authors.lastname: Steen-Johnsen
authors.forename: G
authors.initials: G
authors.lastname: Hopen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000382:microbiology / Q000635:transmission; D002353:Carrier State / Q000382:microbiology / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000032:analysis; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008585:Meningitis, Meningococcal / Q000382:microbiology / Q000635:transmission; D008589:Meningococcal Infections / Q000382:microbiology / Q000517:prevention & control* / Q000635:transmission; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000145:classification*; D009664:Norway; D010406:Penicillins / Q000627:therapeutic use*; D010614:Pharynx / Q000382:microbiology; D012293:Rifampin / Q000627:therapeutic use*; D012703:Serotyping
chemical_list: D004269:DNA, Bacterial; D010406:Penicillins; D012293:Rifampin